PRISMASOL BGK 2/0 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRISMASOL BGK 2/0 IN PLASTIC CONTAINER (PRISMASOL BGK 2/0 IN PLASTIC CONTAINER).
Prismasol BGK 2/0 is a bicarbonate-buffered solution used for continuous renal replacement therapy (CRRT). It provides electrolytes and buffer to correct electrolyte imbalances and acidosis. The mechanism involves replacing lost solutes and maintaining acid-base balance via the bicarbonate buffer system.
| Metabolism | Prismasol components are not metabolized; they are distributed and excreted via renal replacement therapy. Bicarbonate may be converted to carbon dioxide in the blood. |
| Excretion | PRISMASOL BGK 2/0 is a sterile hemofiltration solution for continuous renal replacement therapy (CRRT). Its components (electrolytes, buffers) are not excreted via renal or biliary routes; they are administered as replacement or dialysate fluid and are eliminated primarily through the CRRT circuit and endogenous metabolic pathways. No significant renal or fecal excretion applies; the fluid and solutes are removed via ultrafiltration and diffusion during therapy. |
| Half-life | Not applicable as a drug; PRISMASOL components are endogenous or rapidly equilibrated. The terminal half-life of infused components (e.g., bicarbonate, electrolytes) is minutes to hours depending on patient's metabolic rate and CRRT clearance, with no relevant clinical context for a terminal half-life. |
| Protein binding | Not applicable; components (sodium, chloride, bicarbonate/ lactate/ citrate, potassium, magnesium, calcium, glucose) are ions or small molecules with negligible protein binding (<5% for major ions). |
| Volume of Distribution | Not applicable as a drug; components distribute throughout extracellular fluid volume (approx 0.2 L/kg) and total body water. Clinical meaning: the solution equilibrates with the entire extracellular space. |
| Bioavailability | Intravenous or intra-circuit administration yields 100% bioavailability as it is administered directly into the bloodstream. |
| Onset of Action | Immediate upon administration; the solution acts as a buffer and electrolyte replacement during CRRT, with clinical effect (acid-base correction, electrolyte regulation) occurring within minutes of starting therapy. |
| Duration of Action | Duration is continuous while CRRT is running; the solution is infused or used as dialysate continuously. Clinically, effects on acid-base and electrolyte balance persist as long as therapy is maintained, with immediate offset upon discontinuation. |
Continuous renal replacement therapy (CRRT): 2.0 mEq/L potassium, 2.5 mEq/L calcium, 1.0 mEq/L magnesium; flow rate 2000-3000 mL/h (1000-1500 mL/h if BGK 2/0 is used specifically for hemofiltration). Intravenous via hemodialysis/hemofiltration machine. Not for direct infusion.
| Dosage form | INJECTABLE |
| Renal impairment | Not applicable; product is used in renal replacement therapy and dosing is independent of residual renal function. |
| Liver impairment | No adjustment required; hepatic metabolism is not a significant pathway. |
| Pediatric use | Weight-based: For CRRT in children, typical flow rate is 2000-3000 mL/h/1.73 m², adjusted to body surface area. Potassium content: 2.0 mEq/L; adjust if hypokalemia risk. |
| Geriatric use | No specific adjustment; use standard dose with monitoring of electrolytes and fluid balance due to age-related changes in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRISMASOL BGK 2/0 IN PLASTIC CONTAINER (PRISMASOL BGK 2/0 IN PLASTIC CONTAINER).
| Breastfeeding | There is no known risk to the breastfed infant from the components of PRISMASOL BGK 2/0. The excretion of the solutes into breast milk is not expected to be clinically significant. M/P ratio is not applicable as the product is not a drug with systemic absorption. |
| Teratogenic Risk | PRISMASOL BGK 2/0 IN PLASTIC CONTAINER is a dialysis solution containing electrolytes and glucose. There is no known teratogenic risk. The components are physiological substances that do not cross the placenta in significant amounts to cause fetal harm. Nonetheless, use during pregnancy should be clinically justified. |
■ FDA Black Box Warning
Not for intravenous injection directly; must be used only as a CRRT replacement fluid or dialysate. Serious adverse events can occur with improper use, including electrolyte disturbances and acid-base imbalances.
| Serious Effects |
["Hypersensitivity to any component","Severe metabolic alkalosis","Pre-existing hypercalcemia or hyperkalemia (if not corrected prior)"]
| Precautions | ["Monitor serum electrolytes, acid-base status, and fluid balance frequently","Risk of hypernatremia, hyperkalemia, metabolic alkalosis, or hypocalcemia","Use with caution in patients with severe hepatic failure or lactic acidosis","Do not use if solution is discolored or contains particulate matter"] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes (sodium, potassium, calcium, magnesium, chloride, bicarbonate), blood glucose, and acid-base status regularly. Assess fluid balance and hemodynamic stability. In pregnancy, additional fetal monitoring such as non-stress test or biophysical profile may be considered based on maternal condition. |
| Fertility Effects | There are no known effects on fertility. The components are physiological and not associated with reproductive toxicity. No human data suggest impairment of fertility. |